Eisai Shares Fall Sharply After Japan Panel Seeks More Data for Aduhelm Review
23 December 2021 - 2:27PM
Dow Jones News
By Kosaku Narioka
Eisai Co. shares fell as much as 9.2% early Thursday morning
after a Japanese government panel sought additional data for a
review of the company's Aduhelm drug for Alzheimer's.
Biogen Inc. and Eisai, which co-developed the medication, said
they remained committed to bringing Aduhelm to patients in Japan
soon.
Aduhelm's commercial potential has dropped significantly given
recent regulatory developments in Europe and Japan, as well as
criticism over its regulatory approval in the U.S., Nomura analyst
Motoya Kohtani said in a report.
Earlier this month, the European Medicines Agency recommended
not granting Aduhelm marketing authorization.
Biogen and Eisai said they will continue to engage with Japanese
government officials on additional data requirements.
Eisai shares were 8.8% lower at 6,498 yen ($56.94) at the close
of the morning session in Tokyo.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
December 22, 2021 22:12 ET (03:12 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Eisai Company Ltd (PK) (OTCMarkets): 0 recent articles
More Eisai Company Ltd (PK) News Articles